- Home
- SGML vs COLL Comparison
SGML vs COLL Comparison
Compare SGML & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGML | COLL |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.2B |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SGML | COLL |
|---|---|---|
| Price | $13.09 | $36.63 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $16.75 | ★ $50.83 |
| AVG Volume (30 Days) | ★ 3.1M | 387.1K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | $31.30 | $6.07 |
| Revenue Next Year | $136.50 | N/A |
| P/E Ratio | ★ N/A | $21.55 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $4.25 | $23.23 |
| 52 Week High | $16.88 | $50.79 |
Technical Indicators
Market Signals| Indicator | SGML | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 20.03 |
| Support Level | $10.26 | $34.30 |
| Resistance Level | $16.78 | $39.85 |
| Average True Range (ATR) | 1.14 | 1.58 |
| MACD | -0.16 | -0.78 |
| Stochastic Oscillator | 26.08 | 3.15 |
Price Performance
Historical ComparisonAbout SGML Sigma Lithium Corporation
Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds a 100% interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.